Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Christie

Showing results (31-40 of 60) with videos related to

Pageof 6
Sort By:
Journal of Medical Imaging and Radiation Oncology|June 21, 2023
Patterns of practice regarding use of radiation therapy following radical prostatectomy: A survey of Radiation Oncologists and Urologists in Australia and New ZealandAnna Lawless, Andrew Kneebone, Shreya Armstrong, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|April 27, 2013
Paradoxical metastatic progression following 3 months of neo-adjuvant androgen suppression in the TROG 96.01 trial for men with locally advanced prostate cancerJames W Denham, Allison Steigler, Keen-Hun Tai, et al.
Prostate Cancer|January 16, 2013
Risk Stratification after Biochemical Failure following Curative Treatment of Locally Advanced Prostate Cancer: Data from the TROG 96.01 TrialAllison Steigler, James W Denham, David S Lamb, et al.
Drug Discovery Today|January 17, 2018
The positive impacts of Real-World Data on the challenges facing the evolution of biopharmaJohn Wise, Angeli Möller, David Christie, et al.
The Lancet. Oncology|March 29, 2011
Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trialJames W Denham, Allison Steigler, David S Lamb, et al.
Naunyn-Schmiedeberg'S Archives of Pharmacology|February 25, 2015
Paradoxical effects of the autophagy inhibitor 3-methyladenine on docetaxel-induced toxicity in PC-3 and LNCaP prostate cancer cellsRebecca D Pickard, Briohny H Spencer, Amelia J McFarland, et al.
The Breast Journal|February 27, 2007
Factors determining esthetic outcome after breast cancer conservative treatmentMaria J Cardoso, Jaime Cardoso, Ana C Santos, et al.
The Lancet. Oncology|October 22, 2008
Time to biochemical failure and prostate-specific antigen doubling time as surrogates for prostate cancer-specific mortality: evidence from the TROG 96.01 randomised controlled trialJames W Denham, Allison Steigler, Chantelle Wilcox, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|August 17, 2016
Oligometastatic bone disease in prostate cancer patients treated on the TROG 03.04 RADAR trialSwetha Sridharan, Allison Steigler, Nigel A Spry, et al.
BMJ Open|March 23, 2024
Prostate Cancer Survivorship Essentials for men with prostate cancer on androgen deprivation therapy: protocol for a randomised controlled trial of a tele-based nurse-led survivorship care intervention (PCEssentials Hormone Therapy Study)Anna Green, Robert U Newton, David P Smith, et al.
Pageof 6

Showing results (31-40 of 60) with videos related to

Sort By:
Pageof 6
Journal of Medical Imaging and Radiation Oncology|June 21, 2023
Patterns of practice regarding use of radiation therapy following radical prostatectomy: A survey of Radiation Oncologists and Urologists in Australia and New ZealandAnna Lawless, Andrew Kneebone, Shreya Armstrong, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|April 27, 2013
Paradoxical metastatic progression following 3 months of neo-adjuvant androgen suppression in the TROG 96.01 trial for men with locally advanced prostate cancerJames W Denham, Allison Steigler, Keen-Hun Tai, et al.
Prostate Cancer|January 16, 2013
Risk Stratification after Biochemical Failure following Curative Treatment of Locally Advanced Prostate Cancer: Data from the TROG 96.01 TrialAllison Steigler, James W Denham, David S Lamb, et al.
Drug Discovery Today|January 17, 2018
The positive impacts of Real-World Data on the challenges facing the evolution of biopharmaJohn Wise, Angeli Möller, David Christie, et al.
The Lancet. Oncology|March 29, 2011
Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trialJames W Denham, Allison Steigler, David S Lamb, et al.
Naunyn-Schmiedeberg'S Archives of Pharmacology|February 25, 2015
Paradoxical effects of the autophagy inhibitor 3-methyladenine on docetaxel-induced toxicity in PC-3 and LNCaP prostate cancer cellsRebecca D Pickard, Briohny H Spencer, Amelia J McFarland, et al.
The Breast Journal|February 27, 2007
Factors determining esthetic outcome after breast cancer conservative treatmentMaria J Cardoso, Jaime Cardoso, Ana C Santos, et al.
The Lancet. Oncology|October 22, 2008
Time to biochemical failure and prostate-specific antigen doubling time as surrogates for prostate cancer-specific mortality: evidence from the TROG 96.01 randomised controlled trialJames W Denham, Allison Steigler, Chantelle Wilcox, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|August 17, 2016
Oligometastatic bone disease in prostate cancer patients treated on the TROG 03.04 RADAR trialSwetha Sridharan, Allison Steigler, Nigel A Spry, et al.
BMJ Open|March 23, 2024
Prostate Cancer Survivorship Essentials for men with prostate cancer on androgen deprivation therapy: protocol for a randomised controlled trial of a tele-based nurse-led survivorship care intervention (PCEssentials Hormone Therapy Study)Anna Green, Robert U Newton, David P Smith, et al.
Pageof 6